PDB Short entry for 1IRA HEADER COMPLEX (CYTOKINE RECEPTOR/ANTAGONIST) 09-APR-98 1IRA TITLE COMPLEX OF THE INTERLEUKIN-1 RECEPTOR WITH THE INTERLEUKIN-1 RECEPTOR TITLE 2 ANTAGONIST (IL1RA) COMPND MOL_ID: 1; COMPND 2 MOLECULE: INTERLEUKIN-1 RECEPTOR ANTAGONIST; COMPND 3 CHAIN: X; COMPND 4 SYNONYM: IL1RA; COMPND 5 ENGINEERED: YES; COMPND 6 MOL_ID: 2; COMPND 7 MOLECULE: INTERLEUKIN-1 RECEPTOR; COMPND 8 CHAIN: Y; COMPND 9 FRAGMENT: TYPE I RECEPTOR, EXTRACELLULAR DOMAINS; COMPND 10 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 CELL_LINE: SF9; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_PLASMID: TAC-BSP; SOURCE 9 MOL_ID: 2; SOURCE 10 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 11 ORGANISM_COMMON: HUMAN; SOURCE 12 ORGANISM_TAXID: 9606; SOURCE 13 CELL_LINE: SF9; SOURCE 14 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 15 EXPRESSION_SYSTEM_COMMON: FALL ARMYWORM; SOURCE 16 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 17 EXPRESSION_SYSTEM_CELL_LINE: SF9; SOURCE 18 EXPRESSION_SYSTEM_VECTOR: BACULOVIRUS; SOURCE 19 EXPRESSION_SYSTEM_PLASMID: PVL1392 KEYWDS CYTOKINE RECEPTOR, RECEPTOR ANTAGONIST, IMMUNOGLOBULIN FOLD, COMPLEX KEYWDS 2 (CYTOKINE RECEPTOR-ANTAGONIST), COMPLEX (CYTOKINE RECEPTOR- KEYWDS 3 ANTAGONIST) COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR H.A.SCHREUDER,C.TARDIF,S.TRAMP-KALMEYER,A.SOFFIENTINI,E.SARUBBI, AUTHOR 2 A.AKESON,T.BOWLIN,S.YANOFSKY,R.W.BARRETT REVDAT 6 09-AUG-23 1IRA 1 HETSYN REVDAT 5 29-JUL-20 1IRA 1 COMPND REMARK HETNAM LINK REVDAT 5 2 1 SITE REVDAT 4 04-APR-18 1IRA 1 REMARK REVDAT 3 13-JUL-11 1IRA 1 VERSN REVDAT 2 24-FEB-09 1IRA 1 VERSN REVDAT 1 17-JUN-98 1IRA 0 JRNL AUTH H.SCHREUDER,C.TARDIF,S.TRUMP-KALLMEYER,A.SOFFIENTINI, JRNL AUTH 2 E.SARUBBI,A.AKESON,T.BOWLIN,S.YANOFSKY,R.W.BARRETT JRNL TITL A NEW CYTOKINE-RECEPTOR BINDING MODE REVEALED BY THE CRYSTAL JRNL TITL 2 STRUCTURE OF THE IL-1 RECEPTOR WITH AN ANTAGONIST. JRNL REF NATURE V. 386 194 1997 JRNL REFN ISSN 0028-0836 JRNL PMID 9062194 JRNL DOI 10.1038/386194A0 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH H.SCHREUDER,C.TARDIF,A.SOFFIENTINI,E.SARUBBI,A.AKESON, REMARK 1 AUTH 2 T.BOWLIN,S.YANOFSKY,R.W.BARRETT REMARK 1 TITL CRYSTALS OF SOLUBLE INTERLEUKIN-1 RECEPTOR COMPLEXED WITH REMARK 1 TITL 2 ITS NATURAL ANTAGONIST REVEAL A 1:1 RECEPTOR-LIGAND COMPLEX REMARK 1 REF FEBS LETT. V. 373 39 1995 REMARK 1 REFN ISSN 0014-5793 REMARK 1 REFERENCE 2 REMARK 1 AUTH H.A.SCHREUDER,J.M.RONDEAU,C.TARDIF,A.SOFFIENTINI,E.SARUBBI, REMARK 1 AUTH 2 A.AKESON,T.L.BOWLIN,S.YANOFSKY,R.W.BARRETT REMARK 1 TITL REFINED CRYSTAL STRUCTURE OF THE INTERLEUKIN-1 RECEPTOR REMARK 1 TITL 2 ANTAGONIST. PRESENCE OF A DISULFIDE LINK AND A CIS-PROLINE REMARK 1 REF EUR.J.BIOCHEM. V. 227 838 1995 REMARK 1 REFN ISSN 0014-2956 REMARK 2 REMARK 2 RESOLUTION. 2.70 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : X-PLOR 3.1 REMARK 3 AUTHORS : BRUNGER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.70 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 8.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 97.6 REMARK 3 NUMBER OF REFLECTIONS : 15012 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.213 REMARK 3 FREE R VALUE : 0.314 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 9.900 REMARK 3 FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 8 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.70 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.82 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 86.10 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1463 REMARK 3 BIN R VALUE (WORKING SET) : 0.3930 REMARK 3 BIN FREE R VALUE : 0.4660 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 9.10 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 172 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3638 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 56 REMARK 3 SOLVENT ATOMS : 86 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 45.20 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.004 REMARK 3 BOND ANGLES (DEGREES) : 1.200 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 26.50 REMARK 3 IMPROPER ANGLES (DEGREES) : 1.000 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 5.400 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 11.500; 4.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 8.300 ; 4.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 17.700; 8.000 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PARHCSDX.PRO REMARK 3 PARAMETER FILE 2 : PARAM3_MOD.PRO REMARK 3 PARAMETER FILE 3 : WAT.PAR REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : TOPHCSDX.PRO REMARK 3 TOPOLOGY FILE 2 : TOPH3.CHO REMARK 3 TOPOLOGY FILE 3 : WAT.TOP REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1IRA COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY BNL. REMARK 100 THE DEPOSITION ID IS D_1000174235. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : SEP-94 REMARK 200 TEMPERATURE (KELVIN) : 296 REMARK 200 PH : 7.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : MACSCIENCE M18X REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : GRAPHITE(002) REMARK 200 OPTICS : COLLIMATOR REMARK 200 REMARK 200 DETECTOR TYPE : AREA DETECTOR REMARK 200 DETECTOR MANUFACTURER : SIEMENS REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XDS, XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 15631 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.700 REMARK 200 RESOLUTION RANGE LOW (A) : 60.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 97.2 REMARK 200 DATA REDUNDANCY : 4.700 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.06000 REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.70 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.80 REMARK 200 COMPLETENESS FOR SHELL (%) : 85.3 REMARK 200 DATA REDUNDANCY IN SHELL : 3.10 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.32500 REMARK 200 <I/SIGMA(I)> FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: NULL REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MIR + MOLECULAR REMARK 200 REPLACEMENT REMARK 200 SOFTWARE USED: SQUASH, X-PLOR3.1 REMARK 200 STARTING MODEL: IL1RA STRUCTURE (PDB ENTRY 1ILR) AND TRUNCATED CD4 REMARK 200 DOMAIN (PDB ENTRY 2CD4) REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.00 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.70 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: THE COMPLEX OF THE IL-1 RECEPTOR WITH REMARK 280 THE ANTAGONIST WAS PREPARED BY MIXING A SOLUTION OF IL-1 REMARK 280 RECEPTOR IN 50 MM TRIS (PH 7.5) AND 150 MM NACL WITH A SOLUTION REMARK 280 OF IL1RA IN THE SAME BUFFER. THE COMPLEX WAS CRYSTALLIZED USING REMARK 280 THE HANGING DROP METHOD. THE DROPS WERE PREPARED BY MIXING 4 UL REMARK 280 OF THE PROTEIN SOLUTION WITH 1 UL OF RESERVOIR SOLUTION, REMARK 280 CONTAINING 30% (W/V) PEG 3350, 400 MM MGCL2 IN 100 MM MOPS REMARK 280 BUFFER (PH 7.0)., VAPOR DIFFUSION - HANGING DROP, VAPOR REMARK 280 DIFFUSION, HANGING DROP REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 23.60000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 70.10000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 42.30000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 70.10000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 23.60000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 42.30000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4420 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 22630 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: 6.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: X, Y REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ARG X 1 REMARK 465 PRO X 2 REMARK 465 SER X 3 REMARK 465 GLY X 4 REMARK 465 ARG X 5 REMARK 465 LYS X 6 REMARK 465 GLU X 152 REMARK 465 LEU Y -2 REMARK 465 GLU Y -1 REMARK 465 ALA Y 0 REMARK 465 THR Y 312 REMARK 465 ASN Y 313 REMARK 465 PHE Y 314 REMARK 465 GLN Y 315 REMARK 465 LYS Y 316 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 SER X 7 OG REMARK 470 ASP X 74 CG OD1 OD2 REMARK 470 LYS Y 4 CG CD CE NZ REMARK 470 GLU Y 131 CG CD OE1 OE2 REMARK 470 LYS Y 185 CG CD CE NZ REMARK 470 LYS Y 202 CG CD CE NZ REMARK 470 ASP Y 250 CG OD1 OD2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 SER X 8 -77.58 -95.91 REMARK 500 ASP X 74 -10.69 -141.46 REMARK 500 LYS Y 2 43.34 -78.93 REMARK 500 GLU Y 5 124.99 70.23 REMARK 500 PRO Y 25 76.50 -63.80 REMARK 500 ASP Y 40 -35.60 -32.62 REMARK 500 SER Y 42 -0.99 -58.16 REMARK 500 ARG Y 53 -80.78 -47.35 REMARK 500 GLU Y 69 2.48 -66.90 REMARK 500 SER Y 82 41.84 -146.06 REMARK 500 VAL Y 114 -178.71 -67.23 REMARK 500 ALA Y 115 -42.56 73.84 REMARK 500 PHE Y 128 38.03 -96.95 REMARK 500 LYS Y 158 -115.25 50.94 REMARK 500 ASN Y 165 78.90 52.65 REMARK 500 PRO Y 211 -178.95 -68.58 REMARK 500 ASN Y 296 -167.09 -165.85 REMARK 500 REMARK 500 REMARK: NULL DBREF 1IRA X 1 152 UNP P18510 IL1RA_HUMAN 26 177 DBREF 1IRA Y -2 316 UNP P14778 IL1R1_HUMAN 18 336 SEQRES 1 X 152 ARG PRO SER GLY ARG LYS SER SER LYS MET GLN ALA PHE SEQRES 2 X 152 ARG ILE TRP ASP VAL ASN GLN LYS THR PHE TYR LEU ARG SEQRES 3 X 152 ASN ASN GLN LEU VAL ALA GLY TYR LEU GLN GLY PRO ASN SEQRES 4 X 152 VAL ASN LEU GLU GLU LYS ILE ASP VAL VAL PRO ILE GLU SEQRES 5 X 152 PRO HIS ALA LEU PHE LEU GLY ILE HIS GLY GLY LYS MET SEQRES 6 X 152 CYS LEU SER CYS VAL LYS SER GLY ASP GLU THR ARG LEU SEQRES 7 X 152 GLN LEU GLU ALA VAL ASN ILE THR ASP LEU SER GLU ASN SEQRES 8 X 152 ARG LYS GLN ASP LYS ARG PHE ALA PHE ILE ARG SER ASP SEQRES 9 X 152 SER GLY PRO THR THR SER PHE GLU SER ALA ALA CYS PRO SEQRES 10 X 152 GLY TRP PHE LEU CYS THR ALA MET GLU ALA ASP GLN PRO SEQRES 11 X 152 VAL SER LEU THR ASN MET PRO ASP GLU GLY VAL MET VAL SEQRES 12 X 152 THR LYS PHE TYR PHE GLN GLU ASP GLU SEQRES 1 Y 319 LEU GLU ALA ASP LYS CYS LYS GLU ARG GLU GLU LYS ILE SEQRES 2 Y 319 ILE LEU VAL SER SER ALA ASN GLU ILE ASP VAL ARG PRO SEQRES 3 Y 319 CYS PRO LEU ASN PRO ASN GLU HIS LYS GLY THR ILE THR SEQRES 4 Y 319 TRP TYR LYS ASP ASP SER LYS THR PRO VAL SER THR GLU SEQRES 5 Y 319 GLN ALA SER ARG ILE HIS GLN HIS LYS GLU LYS LEU TRP SEQRES 6 Y 319 PHE VAL PRO ALA LYS VAL GLU ASP SER GLY HIS TYR TYR SEQRES 7 Y 319 CYS VAL VAL ARG ASN SER SER TYR CYS LEU ARG ILE LYS SEQRES 8 Y 319 ILE SER ALA LYS PHE VAL GLU ASN GLU PRO ASN LEU CYS SEQRES 9 Y 319 TYR ASN ALA GLN ALA ILE PHE LYS GLN LYS LEU PRO VAL SEQRES 10 Y 319 ALA GLY ASP GLY GLY LEU VAL CYS PRO TYR MET GLU PHE SEQRES 11 Y 319 PHE LYS ASN GLU ASN ASN GLU LEU PRO LYS LEU GLN TRP SEQRES 12 Y 319 TYR LYS ASP CYS LYS PRO LEU LEU LEU ASP ASN ILE HIS SEQRES 13 Y 319 PHE SER GLY VAL LYS ASP ARG LEU ILE VAL MET ASN VAL SEQRES 14 Y 319 ALA GLU LYS HIS ARG GLY ASN TYR THR CYS HIS ALA SER SEQRES 15 Y 319 TYR THR TYR LEU GLY LYS GLN TYR PRO ILE THR ARG VAL SEQRES 16 Y 319 ILE GLU PHE ILE THR LEU GLU GLU ASN LYS PRO THR ARG SEQRES 17 Y 319 PRO VAL ILE VAL SER PRO ALA ASN GLU THR MET GLU VAL SEQRES 18 Y 319 ASP LEU GLY SER GLN ILE GLN LEU ILE CYS ASN VAL THR SEQRES 19 Y 319 GLY GLN LEU SER ASP ILE ALA TYR TRP LYS TRP ASN GLY SEQRES 20 Y 319 SER VAL ILE ASP GLU ASP ASP PRO VAL LEU GLY GLU ASP SEQRES 21 Y 319 TYR TYR SER VAL GLU ASN PRO ALA ASN LYS ARG ARG SER SEQRES 22 Y 319 THR LEU ILE THR VAL LEU ASN ILE SER GLU ILE GLU SER SEQRES 23 Y 319 ARG PHE TYR LYS HIS PRO PHE THR CYS PHE ALA LYS ASN SEQRES 24 Y 319 THR HIS GLY ILE ASP ALA ALA TYR ILE GLN LEU ILE TYR SEQRES 25 Y 319 PRO VAL THR ASN PHE GLN LYS MODRES 1IRA ASN Y 173 ASN GLYCOSYLATION SITE MODRES 1IRA ASN Y 213 ASN GLYCOSYLATION SITE MODRES 1IRA ASN Y 229 ASN GLYCOSYLATION SITE MODRES 1IRA ASN Y 243 ASN GLYCOSYLATION SITE HET NAG Y 401 14 HET NAG Y 402 14 HET NAG Y 403 14 HET NAG Y 404 14 HETNAM NAG 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE HETSYN NAG N-ACETYL-BETA-D-GLUCOSAMINE; 2-ACETAMIDO-2-DEOXY-BETA- HETSYN 2 NAG D-GLUCOSE; 2-ACETAMIDO-2-DEOXY-D-GLUCOSE; 2-ACETAMIDO- HETSYN 3 NAG 2-DEOXY-GLUCOSE; N-ACETYL-D-GLUCOSAMINE FORMUL 3 NAG 4(C8 H15 N O6) FORMUL 7 HOH *86(H2 O) HELIX 1 1 GLY X 37 LEU X 42 5 6 HELIX 2 2 ILE X 85 ASP X 87 5 3 HELIX 3 3 LYS X 93 PHE X 98 5 6 HELIX 4 4 PRO X 137 GLU X 139 5 3 HELIX 5 5 PRO Y 28 GLU Y 30 5 3 HELIX 6 6 VAL Y 68 ASP Y 70 5 3 HELIX 7 7 ALA Y 104 ALA Y 106 5 3 HELIX 8 8 MET Y 125 PHE Y 128 5 4 HELIX 9 9 GLU Y 168 HIS Y 170 5 3 HELIX 10 10 LYS Y 267 ARG Y 269 5 3 HELIX 11 11 SER Y 283 TYR Y 286 5 4 SHEET 1 A 6 PHE X 146 GLU X 150 0 SHEET 2 A 6 GLN X 11 ASP X 17 -1 N TRP X 16 O TYR X 147 SHEET 3 A 6 ILE X 46 GLU X 52 -1 N VAL X 48 O GLN X 11 SHEET 4 A 6 ALA X 55 GLY X 59 -1 N GLY X 59 O ASP X 47 SHEET 5 A 6 ALA X 99 SER X 105 -1 N PHE X 100 O LEU X 56 SHEET 6 A 6 THR X 108 SER X 113 -1 N GLU X 112 O ILE X 101 SHEET 1 B 2 THR X 22 ARG X 26 0 SHEET 2 B 2 GLN X 29 GLY X 33 -1 N GLY X 33 O THR X 22 SHEET 1 C 2 CYS X 66 SER X 72 0 SHEET 2 C 2 GLU X 75 GLU X 81 -1 N GLU X 81 O CYS X 66 SHEET 1 D 2 PHE X 120 CYS X 122 0 SHEET 2 D 2 SER X 132 THR X 134 -1 N THR X 134 O PHE X 120 SHEET 1 E 4 LEU Y 12 SER Y 15 0 SHEET 2 E 4 TYR Y 83 VAL Y 94 1 N LYS Y 92 O LEU Y 12 SHEET 3 E 4 GLY Y 72 ASN Y 80 -1 N ASN Y 80 O TYR Y 83 SHEET 4 E 4 THR Y 34 TYR Y 38 -1 N TYR Y 38 O TYR Y 75 SHEET 1 F 3 ASP Y 20 ARG Y 22 0 SHEET 2 F 3 LYS Y 60 PHE Y 63 -1 N PHE Y 63 O ASP Y 20 SHEET 3 F 3 ILE Y 54 HIS Y 57 -1 N HIS Y 57 O LYS Y 60 SHEET 1 G 4 PHE Y 108 PRO Y 113 0 SHEET 2 G 4 LYS Y 185 LEU Y 198 1 N GLU Y 194 O PHE Y 108 SHEET 3 G 4 GLY Y 172 TYR Y 182 -1 N TYR Y 182 O LYS Y 185 SHEET 4 G 4 GLN Y 139 LYS Y 142 -1 N TYR Y 141 O THR Y 175 SHEET 1 H 3 GLY Y 118 VAL Y 121 0 SHEET 2 H 3 ARG Y 160 VAL Y 163 -1 N VAL Y 163 O GLY Y 118 SHEET 3 H 3 PHE Y 154 VAL Y 157 -1 N VAL Y 157 O ARG Y 160 SHEET 1 I 4 GLU Y 214 GLU Y 217 0 SHEET 2 I 4 ILE Y 300 ILE Y 308 1 N GLN Y 306 O GLU Y 214 SHEET 3 I 4 PHE Y 290 LYS Y 295 -1 N ALA Y 294 O ASP Y 301 SHEET 4 I 4 ILE Y 237 TRP Y 242 -1 N LYS Y 241 O THR Y 291 SHEET 1 J 4 LEU Y 254 VAL Y 261 0 SHEET 2 J 4 SER Y 270 ILE Y 278 -1 N ASN Y 277 O GLY Y 255 SHEET 3 J 4 ILE Y 224 GLY Y 232 -1 N GLY Y 232 O SER Y 270 SHEET 4 J 4 VAL Y 207 SER Y 210 -1 N SER Y 210 O ASN Y 229 SSBOND 1 CYS X 69 CYS X 116 1555 1555 2.03 SSBOND 2 CYS Y 3 CYS Y 84 1555 1555 2.03 SSBOND 3 CYS Y 24 CYS Y 76 1555 1555 2.03 SSBOND 4 CYS Y 101 CYS Y 144 1555 1555 2.03 SSBOND 5 CYS Y 122 CYS Y 176 1555 1555 2.03 SSBOND 6 CYS Y 228 CYS Y 292 1555 1555 2.02 LINK ND2 ASN Y 173 C1 NAG Y 401 1555 1555 1.45 LINK ND2 ASN Y 213 C1 NAG Y 402 1555 1555 1.45 LINK ND2 ASN Y 229 C1 NAG Y 403 1555 1555 1.45 LINK ND2 ASN Y 243 C1 NAG Y 404 1555 1555 1.45 CISPEP 1 VAL Y 64 PRO Y 65 0 -0.29 CISPEP 2 SER Y 210 PRO Y 211 0 -0.02 CRYST1 47.200 84.600 140.200 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.021186 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011820 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007133 0.00000